RAS Drug Discovery 1st Edition

RAS Drug Discovery, 1st Edition by Adrian Gill and Kevan M. Shokat is an authoritative, practical guide for scientists tackling one of oncology’s most persistent targets. This clear, compelling volume captures attention with its up-to-date synthesis of RAS biology and the translational breakthroughs that have reshaped drug discovery in recent years.

Inside, readers will find a tightly focused exploration of RAS-driven cancers—covering KRAS, NRAS and HRAS mutations—paired with actionable strategies for small-molecule design, covalent inhibition, structure-based approaches, and pathway modulation. Chapters balance mechanistic insight into the GTPase cycle and signaling networks with real-world case studies from medicinal chemistry and clinical development, making complex science accessible without sacrificing rigor.

Ideal for medicinal chemists, cancer biologists, translational researchers, and pharmaceutical scientists, this edition highlights practical workflows used in academic labs and industry teams across North America, Europe and Asia. It emphasizes experimental design, lead optimization, resistance mechanisms, and biomarkers for patient selection—tools that help move candidates from bench to clinic.

What sets this book apart is its combination of expert authorship and actionable content: readers gain both the conceptual frameworks needed to understand RAS pathology and the tactical approaches used to create next-generation inhibitors. Whether you’re designing targeted therapies, advising clinical programs, or training the next generation of researchers, this is a must-have resource.

Order your copy today to add a concise, expertly written reference to your collection. Equip your team with the insights and strategies essential for successful RAS drug discovery and accelerate progress against RAS-driven cancers worldwide.

Note: eBooks do not include supplementary materials such as CDs, access codes, etc.